Highlights from Zacks analyst blog: Disney, Intel, Medtronic, Target and Deere

For immediate release

Chicago, IL – October 27, 2021 – Zacks.com announces the list of stocks featured on the Analysts Blog. Every day, Zacks Equity Research analysts discuss the latest news and events impacting stocks and financial markets. Stocks recently featured in the blog include: The Walt Disney Company DIS, Intel Corporation INTC, Medtronic plc MDT, Target Corporation TGT, and Deere & Company DE.

Here are highlights from Tuesday’s analyst blog:

Third Quarter Earnings Season Scorecard and Analyst Reports for Disney, Intel and Others

Zacks Research Daily features the best research results from our team of analysts. Today’s Research Daily features a real-time dashboard of the current third quarter earnings season, in addition to new research reports on 16 major stocks, including Disney, Intel and Medtronic. These research reports were handpicked from the roughly 70 reports released by our team of analysts today.

You can see all today’s research reports here >>>

Third Quarter Results Season Dashboard

Including all of this morning’s reports, we now have third quarter results for 144 S&P 500 members, or 28.9% of total index members. The total profits of these companies are up + 41.1% compared to the same period last year, with revenues higher by + 15.6%, with 82.6% higher than EPS estimates and 73, 6% to income estimates.

The percentages of EPS and revenue beats are lower than what we had seen from this same group of 144 index members in the previous reporting cycle (Q2 2021), but they are nonetheless above historical averages for this. cohort of companies.

Looking at the third quarter as a whole, combining the actual data released with estimates from upcoming companies, total profits for the quarter are set to increase + 33.4% on revenues up + 14.5%.

Estimates for the current period (Q4 2021) have started to increase, with current revenue growth of + 21.2% expected versus + 20% at the start of September. This is roughly in line with the trend in revisions we saw before the start of the third quarter earnings season, but lower than the trend we had seen in the previous four to six quarters.

For more details on the third quarter earnings season, please see our weekly earnings overview report >>>Big Tech Gains Snapshot: Apple, Microsoft, and Other Tech Giants

Actions of Disney outperformed Zacks Media’s conglomerate industry over the past year (+ 39.5% vs. + 16.4%). The Zacks analyst believes the company has benefited from the growing popularity of Disney +, thanks to a strong content portfolio and a cheaper bundle.

The launch of STAR +, its standalone general entertainment and sports streaming service in Latin America, is expected to further drive subscriber growth in the coming days. The strong performances of Shang Chi and the Legend of the Ten Rings at the box office and upcoming releases are expected to help Studio Entertainment’s revenue growth. The higher programming costs at ESPN and the closure of cruises are some of the main concerns, however.

(You can read the full Disney research report here >>>)

Intelligence stocks have lost -1.8% during the year to date against Zacks General Semiconductor’s industry gain of + 42.2%. Delays in launching chips based on the 7nm process, fierce competition from ARM-based devices, as well as escalating costs weighed on the company’s margins.

Zacks analyst, however, believes that Intel’s leadership position in the PC market, strength in data centers and an advance in process technology are expected to increase the company’s revenue in quarters to to come. Intel also announced, in the third quarter of 2021, its intention to unveil the Mobileye robotaxi equipped with the Mobileye Drive system. This, and a recovering auto industry are other big plus points for the company.

(You can read the full Intel research report here >>>)

Actions of Medtronic have lost -3.6% in the past six months against the loss of -1.9% in Zacks’ medical products industry. The company continues to be under the pressure of adverse currency fluctuations and global economic uncertainties. Several legal and regulatory issues are also likely to weigh on margins in the short term.

Since the start of fiscal 2022, however, Medtronic has experienced strong profit growth. The Zacks analyst believes that this recovery was made possible by the strong flow of new products that the company has brought to the market. The increased pace of mergers and acquisitions and the implementation of a new operating model is likely to add to the recovery momentum.

(You can read the full research report on Medtronic here >>>)

Other noteworthy reports we feature today include Target and Deere.

Media contact

Zacks investment research

800-767-3771 ext 9339

[email protected]


Past performance is no guarantee of future results. The potential for loss is inherent in any investment. This material is provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold any security. No recommendation or advice is given as to whether an investment is suitable for a particular investor. It should not be assumed that any investment in any identified and described securities, companies, sectors or markets was or will be profitable. All information is current as of the date hereof and is subject to change without notice. The views or opinions expressed may not reflect those of the company as a whole. Zacks Investment Research does not engage in investment banking, market making or securities asset management activities. These returns come from hypothetical portfolios composed of stocks with a Zacks rank = 1 that have been rebalanced monthly without any transaction costs. These are not the returns of actual equity portfolios. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for more information on the performance numbers displayed in this press release.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is expected to exceed $ 2.4 trillion by 2028, as scientists develop treatments for thousands of diseases. They are also finding ways to modify the human genome to literally erase our vulnerability to these diseases.

Zacks just released Century of Biology: 7 Biotech Stocks To Buy Now To Help Investors Profit From 7 Stocks That Are Ready to Outperform. Recommendations from previous editions of this report produced gains of + 205%, + 258%, and + 477%. The actions in this report could perform even better.

See these 7 revolutionary actions now >>

Click to get this free report

Intel Corporation (INTC): Free Stock Analysis Report

Target Corporation (TGT): Free shares analysis report

Medtronic PLC (MDT): Free Inventory Analysis Report

Deere & Company (DE): Free Inventory Analysis Report

The Walt Disney Company (DIS): Free Stock Analysis Report

To read this article on Zacks.com, click here.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Source link

Leave a Reply

Your email address will not be published.